DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,374,499 | +21.2% | 17,632 | +17.2% | 0.11% | +6.8% |
| Q2 2023 | $3,610,320 | +0.2% | 15,043 | +5.2% | 0.10% | -11.2% |
| Q1 2023 | $3,602,660 | -42.0% | 14,294 | -38.9% | 0.12% | -18.3% |
| Q4 2022 | $6,213,000 | -6.3% | 23,407 | -8.9% | 0.14% | -23.2% |
| Q3 2022 | $6,634,000 | +12.3% | 25,685 | +10.2% | 0.18% | +20.1% |
| Q2 2022 | $5,907,000 | +242.6% | 23,299 | +107.5% | 0.15% | +670.0% |
| Q4 2019 | $1,724,000 | +6.3% | 11,227 | 0.0% | 0.02% | 0.0% |
| Q3 2019 | $1,622,000 | -98.2% | 11,227 | -98.2% | 0.02% | -91.1% |
| Q2 2019 | $90,331,000 | +19.3% | 632,041 | +10.2% | 0.22% | +15.4% |
| Q1 2019 | $75,742,000 | +33.3% | 573,713 | +4.1% | 0.20% | +18.2% |
| Q4 2018 | $56,835,000 | -5.5% | 551,153 | -0.4% | 0.16% | +9.3% |
| Q3 2018 | $60,150,000 | +6.0% | 553,564 | -3.7% | 0.15% | 0.0% |
| Q2 2018 | $56,740,000 | +29.4% | 574,994 | +28.4% | 0.15% | +28.0% |
| Q1 2018 | $43,856,000 | +28.5% | 447,925 | +21.8% | 0.12% | +26.9% |
| Q4 2017 | $34,124,000 | +1.6% | 367,640 | -6.1% | 0.09% | -5.1% |
| Q3 2017 | $33,593,000 | -11.3% | 391,613 | -12.7% | 0.10% | -14.8% |
| Q2 2017 | $37,872,000 | +7.0% | 448,776 | +8.4% | 0.12% | +2.7% |
| Q1 2017 | $35,401,000 | +26.2% | 413,905 | +14.8% | 0.11% | +19.1% |
| Q4 2016 | $28,054,000 | -15.7% | 360,411 | -15.1% | 0.09% | -16.8% |
| Q3 2016 | $33,265,000 | -20.6% | 424,357 | +2.3% | 0.11% | -24.7% |
| Q2 2016 | $41,879,000 | +5.9% | 414,643 | -0.5% | 0.15% | +4.9% |
| Q1 2016 | $39,538,000 | -18.8% | 416,802 | -20.5% | 0.14% | -17.3% |
| Q4 2015 | $48,667,000 | +9.0% | 523,980 | -0.0% | 0.17% | +3.6% |
| Q3 2015 | $44,655,000 | +2.2% | 524,053 | +2.6% | 0.17% | +9.2% |
| Q2 2015 | $43,700,000 | -0.2% | 510,569 | -1.0% | 0.15% | 0.0% |
| Q1 2015 | $43,773,000 | +0.6% | 515,583 | +1.5% | 0.15% | -0.6% |
| Q4 2014 | $43,531,000 | +12.3% | 507,885 | -0.5% | 0.15% | +10.0% |
| Q3 2014 | $38,780,000 | -26.8% | 510,396 | -24.1% | 0.14% | -27.8% |
| Q2 2014 | $52,977,000 | -17.9% | 672,900 | -21.8% | 0.19% | -22.7% |
| Q1 2014 | $64,527,000 | -4.7% | 860,364 | -1.9% | 0.25% | -6.7% |
| Q4 2013 | $67,719,000 | -17.5% | 877,186 | -25.9% | 0.27% | -23.4% |
| Q3 2013 | $82,095,000 | -1.6% | 1,184,284 | -10.1% | 0.35% | -9.5% |
| Q2 2013 | $83,427,000 | – | 1,317,969 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |